

Continue the Treatment Journey for EGFR+/ALK+ Patients with the IMpower150 Regimen

- A potential survival advantage may extend to EGFR+ patients treated with Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel (ABCP)¹

Prolonged OS


ABCP vs BCP

NE vs 18.7 mo.

HR 0.61 (95% CI 0.29–1.28)

Landmark OS, %	ABCP	BCP
12-month	78.9%	68.9%
18-month	65.0%	53.9%
24-month	65.0%	49.7%

Improved in ORR



- Median duration of response was more than doubled. (ABCP vs BCP: 11.1mo. vs 4.7mo.)



- ABCP has a manageable and familiar safety profile²

immune-related AEs of special interest (n ≥5)

	ABCP		BCP	
	All grades (%)	Grades 3-4%	All grades (%)	Grades 3-4%
Rash	29%	2%	13%	1%
Hepatitis (Laboratory abnormalities)	12%	4%	7%	1%
Hypothyroidism	13%	<1%	4%	0
Pneumonitis	3%	2%	1%	1%
Hyperthyroidism	4%	<1%	1%	0
Colitis	2%	1%	1%	1%
Severe cutaneous reaction	1%	0	<1%	0
Adrenal insufficiency	1%	<1%	1%	<1%
Pancreatitis	1%	1%	0	0

Reference: 1. Reck et al. Lancet Respir Med 2019 May;7(5):387-401; 2. Socinski et al. N Engl J Med 2018; 378:2288-2301

For Healthcare Professionals Only
Before prescribing Tecentriq, please consult the full local prescribing information by visiting <https://www.roche.com.sg/en/pharma/tecentriq.html> or by scanning the following QR code.

